Morgan Stanley
CLYM

Morgan Stanley’s Climb Bio CLYM Stock Holding History

Morgan Stanley’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.6M Buy
234,182
+85,644
+58% +$494K ﹤0.01% 4894
2025
Q4 		$594K Buy
148,538
+62,204
+72% +$149K ﹤0.01% 5419
2025
Q3 		$174K Sell
86,334
-13,125
-13% -$24.4K ﹤0.01% 5941
2025
Q2 		$123K Sell
99,459
-77,520
-44% -$96.5K ﹤0.01% 6055
2025
Q1 		$216K Sell
176,979
-49,871
-22% -$80.9K ﹤0.01% 5700
2024
Q4 		$408K Buy
226,850
+148,669
+190% +$538K ﹤0.01% 5506
2024
Q3 		$398K Buy
78,181
+68,298
+691% +$483K ﹤0.01% 5505
2024
Q2 		$70.3K Buy
9,883
+8,174
+478% +$54.4K ﹤0.01% 6081
2024
Q1 		$4.68K Sell
1,709
-1,709
-50% -$4.7K ﹤0.01% 6907
2023
Q4 		$9.23K Buy
3,418
+1,709
+100% +$4.45K ﹤0.01% 6849
2023
Q3 		$4.5K Hold
1,709
– – ﹤0.01% 6938
2023
Q2 		$4.79K Sell
1,709
-60,607
-97% -$184K ﹤0.01% 6995
2023
Q1 		$181K Buy
62,316
+62,171
+42,877% +$214K ﹤0.01% 5751
2022
Q4 		$532 Sell
145
-4,622
-97% -$13.7K ﹤0.01% 7552
2022
Q3 		$15K Sell
4,767
-1,861
-28% -$5.94K ﹤0.01% 6931
2022
Q2 		$20K Buy
6,628
+946
+17% +$4.48K ﹤0.01% 6994
2022
Q1 		$47K Sell
5,682
-4,440
-44% -$41.4K ﹤0.01% 6740
2021
Q4 		$106K Buy
10,122
+4,009
+66% +$59.8K ﹤0.01% 6408
2021
Q3 		$110K Buy
+6,113
New +$126K ﹤0.01% 6312

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Morgan Stanley's CLYM Position: Q1 2026 in Review

Morgan Stanley increased its Climb Bio (CLYM) stake by 58% in Q1 2026, buying an estimated $494K and bringing the position to 234,182 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #4894.

Morgan Stanley first reported a position in CLYM in Q3 2021 and has held it in 19 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Morgan Stanley held 234,182 shares of Climb Bio worth $1.6M as of Q1 2026.
  • Morgan Stanley bought 85,644 Climb Bio shares in Q1 2026, an estimated $494K.
  • Climb Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4894 holding.
  • Morgan Stanley first reported a position in Climb Bio in Q3 2021 and has held it in 19 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.